Blog
  • Omnichannel
  • Oncology
  • Conferences
  • PERxCEPT
  • Ferma.AI
  • Launch Excellence
Melissa Green

Melissa Green

4 posts •
ASCO20 Delivered Practice-Changing Data in a Highly Accessible, Virtual Format; Despite Reduced Levels of Engagement among Oncologists
Conferences

ASCO20 Delivered Practice-Changing Data in a Highly Accessible, Virtual Format; Despite Reduced Levels of Engagement among Oncologists

Despite the disruption and transition to a completely virtual format, 2020 was not an off-year for ASCO. Nearly all oncologists who attended this year’s ASCO Annual Meeting felt that it represented at

  • Kinga Zapert
    Kinga Zapert
  • Melissa Green
    Melissa Green
  • Nathan DeCarolis
    Nathan DeCarolis
  • Vidhya Hariharan
    Vidhya Hariharan
  • Chloe Moss
    Chloe Moss
  • Carter Broad
    Carter Broad
  • Akshay Krishnan
5 min read
COVID-19: Physician Perspective on Efforts to Address Health Inequity
Covid-19

COVID-19: Physician Perspective on Efforts to Address Health Inequity

Evidence shows that the ongoing COVID-19 pandemic disproportionately impacts Black Americans. Here are some recommendations from physicians to advocate for heath equity.

  • Melissa Green
    Melissa Green
  • Andrew Yukawa
    Andrew Yukawa
  • Manoj Hariharaputhiran
    Manoj Hariharaputhiran
  • Subhadhra Padmanabhan Dhandapani
    Subhadhra Padmanabhan Dhandapani
4 min read
ASCO20 Moves From McCormick Place: Oncologists Prepare for a Virtual Meeting
Conferences

ASCO20 Moves From McCormick Place: Oncologists Prepare for a Virtual Meeting

With the ASCO 2020 Annual Meeting just days away, oncologists are nearly universally planning to “attend” this year’s virtual meeting. However, their participation in the meeting will be less in real-time and

  • Kinga Zapert
    Kinga Zapert
  • Melissa Green
    Melissa Green
  • Vidhya Hariharan
    Vidhya Hariharan
  • Nathan DeCarolis
    Nathan DeCarolis
4 min read
Cardiologists share their perspective on The Medicines Co.'s inclisiran and other key events from AHA's 2019 Scientific Sessions
Conferences

Cardiologists share their perspective on The Medicines Co.'s inclisiran and other key events from AHA's 2019 Scientific Sessions

Following AHA 2019 Scientific Sessions, Novartis announced its intention to buy The Medicines Company for nearly $10B, based on promising results on its small interfering RNA (siRNA) therapy, inclisiran.The therapy targets PCSK9

  • Melissa Green
    Melissa Green
  • Sali Liu
    Sali Liu
4 min read

All rights reserved ZoomRx - 2020.   Privacy Policy


HOME
PERSPECTIVES
PANELISTS
CAREERS